Depomed, Inc.

MENLO PARK, CA -- (Marketwire) -- 02/08/11 -- Depomed, Inc. (NASDAQ: DEPO) announced today that its president and chief executive officer, Carl A. Pelzel will be presenting at the 13th Annual BIO CEO & Investor Conference in New York City on February 15, 2011 at 8:30 am EST. The ... read more

MENLO PARK, CA -- (Marketwire) -- 02/07/11 -- Depomed, Inc. (NASDAQ: DEPO) today announced that in its second Phase 1 pharmacokinetic-pharmacodynamic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric-retentive, extended-release formulation of levodopa/carbidopa, maintained therapeutic blood levels of levodopa over 24 hours in a twice-daily formulation. Two distinct ... read more

MENLO PARK, CA -- (Marketwire) -- 11/17/10 -- Depomed, Inc. (NASDAQ: DEPO) today announced that it ranked number 93 on Technology Fast 500TM, Deloitte's ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Rankings are based on percentage of fiscal year revenue growth during the period ... read more

MENLO PARK, CA -- (Marketwire) -- 11/17/10 -- Depomed, Inc. (NASDAQ: DEPO) today announced that it ranked number 93 on Technology Fast 500™, Deloitte's ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Rankings are based on percentage of ... read more

MENLO PARK, CA -- (Marketwire) -- 11/02/10 -- MENLO PARK, Calif. - November 2, 2010 - Depomed, Inc. (NASDAQ: DEPO) announced today that it has been awarded two cash grants totaling approximately $489,000 under the U.S. Government's Qualifying Therapeutic Discovery Project ("QTDP") program. The QTDP program was part of the Patient Protection and Affordable Care Act signed into ... read more

MENLO PARK, CA -- (Marketwire) -- 11/02/10 -- Depomed, Inc. (NASDAQ: DEPO) announced today that it has been awarded two cash grants totaling approximately $489,000 under the U.S. Government's Qualifying Therapeutic Discovery Project ("QTDP") program. The QTDP program was part of the Patient Protection and Affordable Care Act signed ... read more

MENLO PARK, CA -- (Marketwire) -- 11/01/10 -- Depomed, Inc. (NASDAQ: DEPO) today reported financial results for the third quarter ended September 30, 2010. Revenue for the three months ended September 30, 2010 was $20.1 million and included recognition of $6.0 million in milestones: * a $5.0 million milestone from Janssen ... read more

MENLO PARK, CA -- (Marketwire) -- 11/01/10 -- Depomed, Inc. (NASDAQ: DEPO) today reported financial results for the third quarter ended September 30, 2010. Revenue for the three months ended September 30, 2010 was $20.1 million and included recognition of $6.0 million in milestones: -- a $5.0 million milestone from Janssen ... read more

MENLO PARK, CA -- (Marketwire) -- 11/01/10 -- Depomed, Inc. (NASDAQ: DEPO) today announced that it has received a $2.5 million milestone payment from Merck under its agreement to license certain patents directed to metformin extended release technology for the development of fixed dose combinations of sitagliptin and extended release metformin. "We are pleased that we ... read more

MENLO PARK, CA -- (Marketwire) -- 11/01/10 -- Depomed, Inc. (NASDAQ: DEPO) today announced that it has received a $2.5 million milestone payment from Merck under its agreement to license certain patents directed to metformin extended release technology for the development of fixed dose combinations of sitagliptin and ... read more

MENLO PARK, CA -- (Marketwire) -- 10/26/10 -- Depomed, Inc. (NASDAQ: DEPO) announced today that it will release third quarter 2010 financial results after the market closes on Monday, November 1, 2010. The company will host a conference call beginning at 5:00 p.m. ET, 2:00 p.m. PT to discuss its results. The conference call ... read more

MENLO PARK, CA -- (Marketwire) -- 10/21/10 -- Depomed, Inc. (NASDAQ: DEPO) today announced that it has received a $5 million milestone payment from Janssen Pharmaceutica N.V. following the delivery of a prototype of one of ... read more

MENLO PARK, CA -- (Marketwire) -- 10/21/10 -- Depomed, Inc. (NASDAQ: DEPO) today announced that it has received a $5 million milestone payment from Janssen Pharmaceutica N.V. following the delivery of a prototype of one of four formulations of a fixed dose combination of canagliflozin, a Sodium Glucose ... read more

MENLO PARK, CA -- (Marketwire) -- 10/18/10 -- Depomed, Inc. (NASDAQ: DEPO) announced today that its president and chief executive officer, Carl A. Pelzel will be presenting at the 17th Annual Meeting of NewsMakers in the Biotech Industry Conference on Friday, October 22, 2010 at 9:30 am EST, and at the Oppenheimer 21st Annual Healthcare ... read more

MENLO PARK, CA -- (Marketwire) -- 10/18/10 -- Depomed, Inc. (NASDAQ: DEPO) announced today that its president and chief executive officer, Carl A. Pelzel will be presenting at the 17th Annual Meeting of NewsMakers in the Biotech Industry Conference on Friday, October 22, 2010 at 9:30 am EST, ... read more

MENLO PARK, CA -- (Marketwire) -- 10/11/10 -- Depomed, Inc. (NASDAQ: DEPO) announced today that it has been awarded a clinical grant by The Michael J. Fox Foundation under its Clinical Intervention Awards 2010 program. The modest grant amount supports Depomed in the development of a gastric retentive extended-release tablet of levodopa/carbidopa that targets ... read more

MENLO PARK, CA -- (Marketwire) -- 10/11/10 -- Depomed, Inc. (NASDAQ: DEPO) announced today that it has been awarded a clinical grant by The Michael J. Fox Foundation under its Clinical Intervention Awards 2010 program. The modest grant amount supports Depomed in the development of a gastric retentive ... read more

MENLO PARK, CA -- (Marketwire) -- 10/07/10 -- Depomed, Inc. (Nasdaq: DEPO) today announced presentations of clinical data of Breeze 1 and 2 at the North American Menopause Society (NAMS) Annual Meeting in Chicago, Illinois on October 8, 2010. Both Breeze 1 and 2 are Phase 3 trials that evaluated Serada® (extended release gabapentin ... read more

MENLO PARK, CA -- (Marketwire) -- 09/28/10 -- Depomed, Inc. (NASDAQ: DEPO) announced today that it has received another $500,000 milestone payment after the first formulation that is being developed under its worldwide license agreement with Covidien entered clinical development. The collaboration with Covidien focuses on the exclusive development of up to four acetaminophen/opioid analgesic combination products ... read more

MENLO PARK, CA -- (Marketwire) -- 09/28/10 -- Depomed, Inc. (NASDAQ: DEPO) announced today that it has received another $500,000 milestone payment after the first formulation that is being developed under its worldwide license agreement with Covidien entered clinical development. The collaboration with Covidien focuses on the exclusive ... read more